Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity
Sponsor: Hangzhou Sciwind Biosciences Co., Ltd.
Summary
The aim of the study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of oral ecnoglutide tablets in Chinese participants with overweight or obesity
Official title: A Multicenter, Multiple-dose Escalation, Randomized, Double-blind, Placebo-controlled Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
84
Start Date
2025-11-18
Completion Date
2026-11-22
Last Updated
2026-01-28
Healthy Volunteers
Yes
Interventions
ecnoglutide tablets
oral tablets
placebo with matching dosage
oral tablets
Locations (1)
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China